Express Pharma
Home  »  Market  »  Myriad Genetics partners with Positive Bioscience

Myriad Genetics partners with Positive Bioscience


To offer molecular genetic testing in India

US-based Myriad Genetics has signed a strategic partnership with Positive Bioscience to offer molecular genomic testing in India. These tests will help screen for cancer risks and enable families of cancer patients to take various preventive measures. All testing will be carried out at Myriad’s labs in the US and Germany.

Through this partnership, Positive Bioscience will provide molecular genetic testing for cancer patients and their families. The tests will provide physicians with information to personalise treatment for their cancer patients. Genomic tests are available for nine cancers: breast, pancreatic, ovarian, endometrial, melanoma, prostate, colon, lung and gastric.

Gary King, Executive Vice-President, International Operations, Myriad Genetics said, “We are pleased with our strategic partnership with Positive Bioscience through which Myriad can bring our 25 years of experience in clinical genetic testing to India. Indian patients can now access world leading tests such as BRACAnalysis to identify the risk of developing breast and ovarian cancer, colaris for hereditary colorectal cancer and the myRisk test, which assesses the risk of developing eight cancers.  Our prognostic tests such as EndoPredict for breast cancer and Prolaris for prostate cancer will help to avoid both the over treatment and under-treatment of patients and personalise patient care while reducing the economic burden of treatment. We intend to work closely with Positive Bioscience to make these tests available to Indian clinicians and patients.”

Samarth Jain, Chief Executive Officer, Positive Bioscience said, “Positive Bioscience is pleased to work with Myriad to offer molecular genetic testing in India.  These tests will help patients by providing insights into potential healthcare challenges they may encounter and improve the quality of their lives.”

EP News BureauMumbai

Comments are closed.